{
    "clinical_study": {
        "@rank": "98950", 
        "acronym": "NIHCAP", 
        "arm_group": [
            {
                "arm_group_label": "Point-of-Care diagnostic laboratory test", 
                "arm_group_type": "Experimental", 
                "description": "Adult patients with community-acquired pneumonia (CAP) who are in the Targeted strategy group will undergo point-of-care (POC) diagnostic laboratory tests."
            }, 
            {
                "arm_group_label": "Empiric therapy", 
                "arm_group_type": "No Intervention", 
                "description": "Option of no application of POC laboratory tests"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective interventional study  to assess laboratory testing which will identify\n      the microbial cause of pneumonia. This, in turn, will allow targeted antimicrobial agent\n      selection for patients with community acquired-pneumonia (CAP).\n\n      Hypothesis: 1) To determine if Targeted strategy is non-inferior to Empiric therapy with\n      respect to outcome endpoints. 2) To assess the use of innovative POC tests allows targeted\n      narrow-spectrum antimicrobial therapy. 3) To determine if Targeted strategy is superior to\n      Empiric therapy in patients with viral pneumonia"
        }, 
        "brief_title": "Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Community-acquired Pneumonia", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "detailed_description": {
            "textblock": "The study will be conducted at five academic medical university sites with 7 hospitals.\n      Empiric therapy is defined as selection of antibiotic therapy based on the 2007 ATS-IDSA\n      guidelines in which broad-spectrum antibiotics are recommended, and microbial cause is\n      uncertain"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        \u25cf  Adult patients greater than age 17 years who are initially evaluated in the ED with\n        symptoms of CAP. This includes those who will be treated as outpatients and those admitted\n        to the hospital (both ward and ICU).\n\n        The definition of CAP is as follows:\n\n          -  Presence of pulmonary infiltrates on chest radiography.  (Initial reading may be\n             performed by the ED physician - but has to be confirmed by board certified\n             radiologist for inclusion in the study).\n\n          -  At least 2 of the following: new onset of cough, productive sputum, shortness of\n             breath, chest pain, fever > 380C, abnormal chest auscultation, WBC > 12,000 cells/mL.\n\n          -  Able to provide informed consent\n\n          -  Read, signed, and dated informed consent document\n\n          -  Available for follow-up for the planned duration of the study\n\n        Exclusion Criteria:\n\n          -  Patients with underlying immunosuppressive illness (HIV, neutropenia, asplenia,\n             transplant recipient, cystic fibrosis, receipt of immunosuppressive medications\n             including corticosteroids, (equivalent of prednisone > 10 mg) cancer chemotherapy, or\n             anti-tumor necrosis factor agents.\n\n          -  Patients residing in long-term care facilities"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662258", 
            "org_study_id": "HHSN272201000040C"
        }, 
        "intervention": {
            "arm_group_label": "Point-of-Care diagnostic laboratory test", 
            "description": "All POC tests are FDA-cleared.", 
            "intervention_name": "Point-of-Care diagnostic laboratory test", 
            "intervention_type": "Device", 
            "other_name": [
                "The POC tests are:", 
                "FilmArray (Idaho Tech, Salt Lake City, UT)", 
                "Xpert Flu (Cepheid, Sunnyvale, CA)", 
                "Vidas Brahms Procalcitonin (BioMerieux, Durham, NC)", 
                "Urinary antigen for Strep pneumoniae (Alere, Waltham, MA)", 
                "Legionella BinaxNOW urinary antigen(Alere, Waltham, MA)", 
                "Gram stain of respiratory secretions"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Anti-Infective Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Community-acquired pneumonia", 
            "Targeted strategy", 
            "Empiric therapy"
        ], 
        "lastchanged_date": "August 7, 2012", 
        "location": [
            {
                "contact": {
                    "email": "j.ramirez@louisville.edu", 
                    "last_name": "Julio Ramirez, M.D.", 
                    "phone": "502-852-7844"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "University of Louisville"
                }, 
                "investigator": {
                    "last_name": "Julio Ramirez, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jb@jhmi.edu", 
                    "last_name": "John Bartlett, M.D.", 
                    "phone": "410-955-5464"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins"
                }, 
                "investigator": {
                    "last_name": "John Bartlett, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dmildvan@chpnet.org", 
                    "last_name": "Donna Mildvan, M.D.", 
                    "phone": "212-420-4005"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10003"
                    }, 
                    "name": "Beth Israel"
                }, 
                "investigator": {
                    "last_name": "Donna Mildvan, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "filet@summa-health.org", 
                    "last_name": "Thomas File, M.D.", 
                    "phone": "330-375-3894"
                }, 
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44304"
                    }, 
                    "name": "Summa Health System"
                }, 
                "investigator": {
                    "last_name": "Thomas File, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "daniel.musher@va.gov", 
                    "last_name": "Daniel Musher, M.D.", 
                    "phone": "713-791-1414", 
                    "phone_ext": "5420"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine"
                }, 
                "investigator": {
                    "last_name": "Daniel Musher, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For Community-Acquired Pneumonia", 
        "other_outcome": [
            {
                "description": "Antiviral agents will be administered at POC (point-of-care) if Influenza virus is identified by molecular testing. Penicillin compounds will be administered if Strep pneumoniae is identified.  Macrolides/quinolone will be administered if Mycoplasma pneumoniae and Legionella are identified. Etc.", 
                "measure": "Receipt of narrow spectrum antimicrobial agent targeted toward a specific microbe (as opposed to empiric antimicrobial therapy that is broad-spectrum)", 
                "safety_issue": "No", 
                "time_frame": "30 days after enrollment although most patients will be evaluable within 5 days"
            }, 
            {
                "description": "Educational measures using evidence-based endpoints for clinical response will lead to shorter LOS without concomitant increase in complications or clinical failure.", 
                "measure": "Length of stay (LOS) for hospitalized patients", 
                "safety_issue": "No", 
                "time_frame": "30 days after enrollment"
            }
        ], 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Victor L Yu, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Symptoms of sputum, cough, shortness of breath. Objective signs of deterioration: Acute Respiratory Distress Syndrome, empyema,nonpulmonary infection by infecting microbe, ICU admission, rehospitalization within 7 days following discharge", 
            "measure": "Improvement or resolution of symptoms of CAP AND absence of objective signs of deterioration", 
            "safety_issue": "No", 
            "time_frame": "30 days after enrollment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662258"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pittsburgh", 
            "investigator_full_name": "Victor Yu", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "POC microbiology testing including gram stain of respiratory secretions, blood culture, molecular probes.", 
            "measure": "Identification of microbial etiology by laboratory testing", 
            "safety_issue": "No", 
            "time_frame": "30 days following  enrollment, although microbial identification usually occurs within 5 days."
        }, 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Louisville", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Louisville Veterans Affairs Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Johns Hopkins University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Summa Health System", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Baylor College of Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ben Taub Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Houston VA Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Beth Israel Medical Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}